Saturday, July 25, 2026

pharma · Melanoma · Tumor · NKTR

Nektar Therapeutics UK

Nektar Therapeutics UK clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

455 Mission Bay Boulevard South, San Francisco, California 94158, US HQ
1990 Founded
610 Employees
Public company Type
NKTR · NYSE Ticker
Company details
Status
Public
HQ
455 Mission Bay Boulevard South, San Francisco, California 94158, US
Founded
1990
Employees
610
Programs
3
Drugs
17
Patents
2
Intelligence · Clinical Programs

Nektar Therapeutics UK projects

3 ClinicalTrials.gov programs sponsored by Nektar Therapeutics UK.

Nektar Therapeutics UK has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. NKTR-102 100 mg/m2

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial
  2. NKTR-102 q14d

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial
  3. Nivolumab

    Nektar Therapeutics UK Limited

    Ependymoma

    phase 2 mab terminated

    1 trial

Frequently asked questions

How many clinical projects does Nektar Therapeutics UK have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.